A groundbreaking therapy has shown remarkable results in treating aggressive and incurable blood cancers, offering new hope to patients who once faced a grim prognosis. This innovative treatment involves a precise DNA editing technique that transforms white blood cells into potent cancer-fighting agents, effectively turning them into 'living drugs'.
The story of the first patient, a young girl, was previously reported in 2022, and her remarkable recovery has inspired her to pursue a career in cancer research. Since then, eight children and two adults with T-cell acute lymphoblastic leukaemia have been treated, with an impressive 64% of patients achieving remission. The treatment, conducted at Great Ormond Street Hospital, involved a complex process of editing the DNA of white blood cells, enabling them to target and destroy cancerous cells while leaving healthy cells intact.
For patients on the trial, traditional treatments like chemotherapy and bone marrow transplants had failed, leaving a dire prognosis. However, the experimental therapy provided a glimmer of hope, focusing on making their remaining time more comfortable rather than curing the disease. Alyssa Tapley, a 16-year-old from Leicester, who was the first person in the world to receive this treatment, now leads a fulfilling life, free of cancer. Her story exemplifies the transformative power of this cutting-edge therapy.
The treatment involves a three-step DNA editing process. First, the T-cells' targeting mechanism is disabled to prevent them from attacking the patient's body. Second, a chemical marking called CD7 is removed, which is crucial for preventing the therapy from self-destructing. Finally, an 'invisibility cloak' is added to protect the modified T-cells from being killed by chemotherapy drugs. This ensures that the modified T-cells can effectively hunt and destroy cancerous cells without harming healthy cells.
The therapy is administered to patients, and if their cancer is undetectable after four weeks, they undergo a bone marrow transplant to regenerate their immune system. This intensive treatment, while demanding on patients, has yielded remarkable results. Prof Waseem Qasim from UCL and Great Ormond Street Hospital emphasizes that the therapy's success lies in its ability to dismantle the entire immune system, a challenging feat that has been achieved with impressive outcomes.
The study, published in the New England Journal of Medicine, reports that nine out of the first 11 patients treated achieved deep remission, enabling them to undergo a bone marrow transplant. Seven of these patients remain disease-free, ranging from three months to three years after treatment. However, the therapy is not without risks, including the potential for infections during the immune system's recovery period. In two cases, the cancer managed to evade the treatment by losing its CD7 markings, highlighting the ongoing challenges in this field.
Despite these challenges, the results are considered striking, offering hope to patients with aggressive leukaemia. Dr Robert Chiesa from Great Ormond Street Hospital expressed his satisfaction in providing hope to patients who had otherwise lost it. Dr Deborah Yallop, a consultant Haematologist at King's College Hospital, praised the therapy's effectiveness in clearing incurable leukaemia. Dr Tania Dexter, a senior medical officer at UK stem cell charity Anthony Nolan, added that the results bring hope for further advancements in such treatments, making them accessible to more patients.
